Targeting Ang II signaling may impede tumor progression in patients and experimental models of cancer [9]–[11], as the invasiveness and immunosuppression state of many types of cancer is dependent on the up-regulation of AT1 receptor [12], [13]. This evidence concerns the gene AGTR1 and cancer.